Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768252 | 0.93 | TSHR (0.61) | TSHRIDO1MAOBALDH1A1TDP1 | |
| Bromobenzene SCHEMBL17868575 | 0.93 | TSHR (0.75) | TSHRIDO1MAOBALDH1A1TDP1 | |
| SCHEMBL9342895 | 0.90 | IDO1 (0.64) | TSHRIDO1MAOBAPPRXRA | |
| SCHEMBL649020 | 0.90 | IDO1 (0.64) | TSHRIDO1MAOBAPPRXRA | |
| SCHEMBL8486861 | 0.89 | TSHR (0.62) | TSHRIDO1MAOBARLMNA | |
| SCHEMBL9795394 | 0.87 | TSHR (0.94) | TSHRIDO1MAOBAGXT | |
| SCHEMBL2658064 | 0.87 | TSHR (0.54) | TSHRIDO1MAOBTDP1CHRM3 | |
| SCHEMBL11361280 | 0.86 | IDO1 (0.54) | TSHRIDO1MAOBALDH1A1TDP1 | |
| SCHEMBL3686733 | 0.86 | TSHR (0.52) | TSHRIDO1MAOBTDP1CHRM3 | |
| SCHEMBL14503428 | 0.85 | TSHR (0.52) | TSHRIDO1MAOBARCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| CN-103261185-A | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORP | 2013-08-21 | — | — | CN | disclosed |
| CN-102482280-A | [1,2,4] triazolo [4,3-b ] pyridazines as ligands for androgen receptors | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-7217701-B2 | Intracellular calcium concentration increase inhibitors | KATSUHIKO MIKOSHIBA (JP) | 2007-05-15 | — | — | US | disclosed |
| WO-2005040127-A1 | NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2005-05-06 | — | — | WO | disclosed |
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | MIKOSHIBA, KATSUHIKO (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1444981-A1 | INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS | Mikoshiba, Katsuhiko (JP) | 2004-08-11 | — | — | EP | disclosed |
| EP-1021423-A1 | MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF$g(a) SECRETION | Abbott Laboratories (US) | 2000-07-26 | — | — | EP | disclosed |
| US-5952320-A | USEFUL IN THE TREATMENT OF DISEASES IN WHICH MATRIX METALLOPROTEINASE PLAY A ROLE; MATRIX METALLOPROTEINASE INHIBITING COMPOSITIONS | ABBOTT LABORATORIES (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1998030551-A1 | MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNFα SECRETION | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0328643-B1 | (alpha)-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION | TERUMO CORP (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0328643-A1 | (alpha)-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION | TERUMO KABUSHIKI KAISHA (JP) | 1989-08-23 | — | — | EP | disclosed |
| US-4115383-A | Alkoxycarbonyl-ethylthio-azetidinones and process for their preparation | ELI LILLY AND COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4048162-A | Process for preparing 3-hydroxy cephalosporins | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4008230-A | Process for preparing 3-hydroxy cephalosporins | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | TSHR 64/4885IDO1 2580/4885MAOB 3545/4885 |
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | CAB39, BPGM, ORAI1 | TSHR 3019/4885IDO1 2749/4885MAOB 2523/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | TSHR 64/4885IDO1 2628/4885MAOB 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.